메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

HEISR's Kickstarter-Favorite 3-Sided Toothbrush Returns to the U.S. for Black Friday, Offering Faster, Deeper, and Gentler Daily Cleaning

LAS VEGAS, Nov. 28, 2025 -- The 3-sided electric toothbrush that gained strong support on Kickstarter in 2023 is officially returning to the U.S. this Black Friday. As more users seek practical upgrades to their everyday routines, HEISR reintroduces its patented wrap-around design known for deeper inner-surface cleaning, up to 75% faster brushing, and a noticeably gentler experience for sensitive gums. A New Approach to Everyday Oral Hygiene Rather than relying on stronger motors or additional modes, HEISR redesigned the brushing method itself. The patented wrap-around
- 김갑성 기자
- 2025-11-28 23:15
HZICC：Innovation hub: Hangzhou witness new voices and new ambitions

HANGZHOU, China, Nov. 28, 2025 -- The remarkable achievements of past winners of Hangzhou's Innovation & Entrepreneurship Competition for Overseas Talents have set a powerful example, inspiring a new wave of international innovators to bring their projects to Hangzhou. Among this year's competitors, Huang Yuanhui is an innovator from the Technical University of Munich, who introduced "NeuroMusician," a wearable device that modulates brainwaves to alleviate stress and improve sleep. "The device uses AI to help users achieve mental calmness and deeper sleep--all within
- 김갑성 기자
- 2025-11-28 21:25
HZICC：Unlocked potential: why global innovators choose Hangzhou

HANGZHOU, China, Nov. 28, 2025 -- Meng Jintao, winner of the 2024 Hangzhou's Innovation & Entrepreneurship Competition for Overseas Talents, exemplifies this journey. His project on "All-Iron Redox Flow Battery Technology"--dubbed a "giant movable power bank"--has already secured letters of intent totaling over RMB 2.5 billion. But his success extends beyond the competition. "As a Zhejiang native, Hangzhou's mix of strategic location, academic resources, and pro-innovation policies has made the city obviously attractive," Meng reflects. Since winning,
- 김갑성 기자
- 2025-11-28 21:19
BioDlink Showcases Europe-China CMC Collaboration Amid Developmental Breakthrough

Recognized as Biologics CDMO of the Year, BioDlink shares insights into the world's first approved EGFR-targeted ADC for recurrent/metastatic nasopharyngeal carcinoma The company enables seamless Europe–China tech transfer and faster biologics development through an integrated, end-to-end CMC platform SUZHOU, China, Nov. 28, 2025 -- BioDlink, a global leader in biologics contract development and manufacturing, took center stage at Biologics CDMO Europe 2025 to present its critical role in the regulatory approval and manufacturing support of the world's first approved EGF
- 김갑성 기자
- 2025-11-28 21:00
Angel Yeast's 8,500-Ton Specialty Yeast Facility and New Brewing Microbial Pilot Platform Come Online

YICHANG, China, Nov. 28, 2025 -- Angel Yeast (SH600298), a global leader in yeast and fermentation solutions, has begun trial production at its new specialty yeast project in the Baiyang Biotechnology Park, Yichang High‑tech Zone. The facility commenced material feeding on August 31 and, once fully ramped, will reach an annual capacity of 8,500 tons. This launch completes Angel Yeast's full-chain layout in specialty yeast—from R&D and pilot‑scale production to scaled manufacturing—enhancing supply of high-value yeast‑derived ingredients for craft brewing, wine, and bioenergy, and
- 김갑성 기자
- 2025-11-28 20:58
Inaticabtagene Autoleucel (YORWIDATM) New Drug Application for Lymphoma Approved, China's innovative CAR-T Enters a New Era of Dual Indications

BEIJING, Nov. 28, 2025 -- On November 28, 2025, Juventas Cell Therapy Co., Ltd. (hereinafter referred to as "Juventas") announced that its independently developed CAR-T cell therapy product, Inaticabtagene Autoleucel (Ina-cel) (tradename: YORWIDATM), has received new drug marketing approval from the China National Medical Products Administration (NMPA). This approval is for the treatment of relapsed or refractory Large B-Cell Lymphoma (r/r LBCL) after two or more lines of systemic therapy. This is the second approved indication in China for Ina-cel, following its initial approval in
- 김갑성 기자
- 2025-11-28 20:52
K-Beauty & K-MediTech Expo Malaysia 2025 Concludes Successfully, Strengthening Korea-Malaysia Collaboration Across Beauty and Healthcare Sectors

PENANG, Malaysia, Nov. 28, 2025 -- K-Beauty Expo Malaysia 2025 and K-MediTech Expo Malaysia 2025, hosted by Gyeonggi Province and organised by KINTEX, have successfully concluded at the Penang Waterfront Convention Centre (PWCC) after a dynamic three-day showcase of Korea's leading beauty and medical innovations. Making their Malaysian debut, the dual expos drew thousands of visitors, buyers, healthcare professionals, and beauty enthusiasts from across Southeast Asia. The opening ceremony was graced by distinguished VIPs, including Mr. Sang-woo Hong, Ambassador for Internationa
- 김갑성 기자
- 2025-11-28 20:11
Tianlong Strengthens Transfusion Safety with Innovative Blood Screening Solutions on World AIDS Day 2025

XI'AN, China, Nov. 28, 2025 -- On World AIDS Day 2025, Tianlong reiterates its commitment to advancing global transfusion safety by presenting its fully integrated nucleic acid blood screening solution. Combining high automation with high-sensitivity NAT reagents, the solution enables earlier detection of low-viral-load infections—an essential step in reducing transfusion-transmitted HIV and safeguarding patients who rely on safe blood. Strengthening Blood Safety Through Earlier Detection Ensuring blood safety remains one of the most effective defenses against transfusio
- 김갑성 기자
- 2025-11-28 18:33
SPOT-MAS Launches in Taiwan: AI-Powered Multi-Cancer Early Detection Ushers in a New Era of Precision Medicine

TAIPEI, Nov. 28, 2025 -- Precision medicine is entering a new era, driven by breakthroughs in genetic technology and Artificial Intelligence (AI). Multi-Cancer Early Detection (MCED) has become a global trend, and Taiwan joins this movement with the introduction of SPOT-MAS - an advanced screening solution developed by Gene Solutions, a global leader in precision oncology and genomics, in collaboration with local partner Gene Health. The launch event, "Gene Solutions • Decoding Tomorrow - SPOT-MAS Taiwan Launch & Sharing Session," held on November 22, brought together lea
- 김갑성 기자
- 2025-11-28 16:03
OMRON Healthcare Surpasses 50 Million Nebulizers Sold

[ 메디채널 김갑성 기자 ] - Easing Burden of Respiratory Diseases Worldwide since 1978 - KYOTO, Japan, Nov. 28, 2025 -- OMRON HEALTHCARE Co., Ltd., a global leader in the field of clinically proven, innovative medical equipment for home health monitoring and treatment, announced that cumulative sales of its nebulizers have surpassed 50 million units. This proud milestone underscores the company's long-standing commitment to helping people around the world to live healthier lives through management of respiratory conditions. Image1: https://cdn.kyodonewsprwire.jp/prwfile/release/M000242/
- 김갑성 기자
- 2025-11-28 16:00

이전

31 32 33 34 35 36 37 38 39 40

많이 본 기사

최근기사

2026-01-01_THU

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 01월 01일 22시 40분